Ocustin Ophthalmic Solution

Introduction

Bepotastine besilate is an antihistamine used primarily for the treatment of allergic conditions such as allergic rhinitis and urticaria (hives). It is known for its selective H1 receptor antagonism and low potential for causing sedation.

Uses

Bepotastine besilate is used for:

Relief of symptoms associated with allergic rhinitis, including sneezing, runny nose, and itching.
Treatment of chronic urticaria to relieve itching and hives.

It is effective in managing these symptoms by blocking the action of histamine, a chemical involved in allergic responses.

Brand Name	Ocustin
Type	Ophthalmic Solution
Weight	1.5%
Generic	Bepotastine Besilate
Manufacturer	Popular Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Bepotastine besilate works by selectively antagonizing histamine H1 receptors. By binding to these receptors, it prevents histamine from exerting its effects, which include vasodilation, increased vascular permeability, and smooth muscle contraction. This results in a reduction of allergic symptoms such as itching, swelling, and redness.

How Long Does It Take to Work?

Bepotastine besilate typically starts to work within 1 to 2 hours after administration, with peak effects occurring around 2 to 3 hours. The duration of action can last up to 24 hours, making it suitable for once-daily dosing.

Absorption

Bepotastine besilate is rapidly absorbed after oral administration. The peak plasma concentration is usually reached within 1 to 2 hours. Its absorption may be influenced by the presence of food, though it is generally not significantly affected.

Route of Elimination

Bepotastine besilate is metabolized in the liver and excreted primarily through the urine. A small fraction of the drug is eliminated unchanged in the urine, while most is metabolized to inactive metabolites before excretion.

Dosage

The recommended therapy is 1 drop of Bepotastine sterile Eye Drops in the affected eye(s) twice daily.

Pediatric Use: Safety and efficacy in pediatric patients below the age of 2 have not been established.

For adults and children over 12 years:

The usual oral dosage is 10 mg twice daily.

For children aged 2 to 11 years, the dosage may be adjusted based on body weight and clinical response. Dosage should be individualized according to patient needs and tolerability.

Administration

Bepotastine besilate is administered orally. Tablets should be taken with water, with or without food. Consistency in administration time is recommended for optimal results.

Side Effects

Common side effects may include:

Drowsiness.
Dry mouth.
Headache.
Fatigue.

Less common side effects include gastrointestinal disturbances such as nausea or diarrhea.

Toxicity

Toxicity from bepotastine besilate is rare but may occur with overdose or excessive use. Symptoms of toxicity may include severe drowsiness, dizziness, or gastrointestinal symptoms. Immediate medical attention is required in cases of suspected overdose.

Precautions

Precautions include:

Use with caution in patients with a history of hepatic or renal impairment.
Monitor for signs of sedation, especially when initiating therapy or adjusting the dose.
Be cautious in patients with a history of allergies or sensitivity to other antihistamines.

Interaction

Bepotastine besilate may interact with other central nervous system depressants, such as alcohol or benzodiazepines, increasing the risk of sedation. It is advisable to avoid combining these substances unless under medical supervision.

Disease Interaction

Use bepotastine besilate with caution in patients with:

Hepatic or renal impairment.
History of gastrointestinal disorders.

Adjustments to dosing or frequency may be necessary based on individual health conditions.

Drug Interaction

Drug interactions may occur with other antihistamines or medications affecting the central nervous system. It is important to consult a healthcare provider before starting or stopping any medications while on bepotastine besilate.

Food Interactions

There are no significant food interactions with bepotastine besilate. However, it is generally recommended to take the medication consistently with or without food to maintain stable drug levels.

Pregnancy Use

Bepotastine besilate is classified as a Category C drug by the FDA, indicating that risk cannot be ruled out during pregnancy. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult a healthcare provider for advice if pregnant or planning to become pregnant.

Lactation Use

Bepotastine besilate is excreted into breast milk in small amounts. It is generally advised to avoid breastfeeding while on this medication. Consult a healthcare provider to discuss the risks and benefits of use during lactation.

Acute Overdose

Acute overdose of bepotastine besilate may cause severe drowsiness, dizziness, or gastrointestinal symptoms. In cases of overdose, seek immediate medical attention for appropriate management and treatment.

Contraindication

Bepotastine besilate is contraindicated in patients with:

Known hypersensitivity to bepotastine or other components of the formulation.
Severe hepatic or renal impairment without appropriate adjustments.

Use Direction

Follow the healthcare provider’s instructions for dosage and administration. Do not exceed the recommended dose, and avoid combining with other central nervous system depressants unless advised by a healthcare provider.

Storage Conditions

Store bepotastine besilate at room temperature, away from moisture and heat. Keep the medication out of reach of children, and ensure the container is tightly closed.

Volume of Distribution

The volume of distribution for bepotastine besilate is approximately 1.2 L/kg, indicating moderate distribution throughout body tissues.

Half Life

The half-life of bepotastine besilate is approximately 2.5 to 3 hours, allowing for twice-daily dosing in most cases.

Clearance

Bepotastine besilate is primarily cleared through hepatic metabolism and renal excretion. The clearance rate may be affected by liver or kidney function, necessitating dose adjustments in affected individuals.

See in details version Ocustin Ophthalmic Solution 1.5% also Ocustin Ophthalmic Solution 1.5% in bangla